Clinical Trial Detail

NCT ID NCT02668653
Title Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Daiichi Sankyo Inc.
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin + Idarubicin

Cytarabine + Daunorubicin + Idarubicin + Quizartinib

Age Groups: senior adult

Additional content available in CKB BOOST